The fibrinolytic system is the body's endogenous mechanism for dissolving established thrombi and maintaining vascular patency after the coagulation cascade has fulfilled its hemostatic function. Pharmacological thrombolysis exploits this system by delivering exogenous plasminogen activators that dramatically accelerate clot dissolution, converting a process that normally takes days to hours or minutes. Understanding the molecular physiology of fibrinolysis is prerequisite to rational use of thrombolytic agents and their reversal strategies.
Plasminogen and Plasmin: The Core Effector System. The fibrinolytic system centers on the zymogen plasminogen (an inactive serine protease precursor synthesized in the liver and present in plasma at concentrations of approximately 2 micromolar) and its active form, plasmin. Plasminogen circulates in two conformations: the closed Glu-plasminogen form, which is relatively resistant to activation, and the open Lys-plasminogen form, which is generated by limited plasmin cleavage and has substantially higher affinity for fibrin and plasminogen activators. Plasminogen binds to fibrin clots via lysine-binding sites in its kringle domains, concentrating it at the site of thrombus. Plasmin, once generated, cleaves fibrin at multiple arginine-lysine bonds, producing soluble fibrin degradation products (FDPs) including D-dimer, which serves as a clinical biomarker of fibrinolysis. Plasmin has a broad substrate profile: in addition to fibrin it cleaves fibrinogen, factor V, factor VIII, and von Willebrand factor (vWF), which accounts for the systemic bleeding risk associated with thrombolytic therapy when plasminogen activation is not confined to the thrombus surface.1
Physiological Plasminogen Activators. Two endogenous serine proteases activate plasminogen by cleaving a single arginine-valine bond to generate the active two-chain plasmin: tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Tissue-type plasminogen activator (tPA) is synthesized and released by vascular endothelial cells in response to thrombin, fibrin, histamine, and shear stress. It has a short plasma half-life of approximately 5 minutes due to rapid clearance by hepatic receptors and inhibition by plasminogen activator inhibitor-1 (PAI-1). The defining pharmacological property of tPA is its fibrin specificity: tPA has very low catalytic activity for plasminogen in free solution but is dramatically (approximately 1,000-fold) more active when bound to fibrin, effectively concentrating plasminogen activation at the clot surface and limiting systemic plasmin generation. Urokinase-type plasminogen activator (uPA) is produced by renal epithelial cells, macrophages, and fibroblasts; it activates plasminogen in both free solution and fibrin-bound forms, making it less fibrin-specific than tPA. Streptokinase, a bacterial protein derived from beta-hemolytic streptococci, is a non-enzymatic plasminogen activator that forms a 1:1 stoichiometric complex with plasminogen, inducing a conformational change that renders the complex catalytically active toward free plasminogen; it has no fibrin specificity.12
Endogenous Regulation of Fibrinolysis. The fibrinolytic system is under tight physiological regulation by two principal inhibitors. Plasminogen activator inhibitor-1 (PAI-1, also designated SERPINE1) is a serine protease inhibitor (serpin) that rapidly inactivates both tPA and uPA by forming a covalent 1:1 complex with their active sites; PAI-1 is the principal physiological regulator of tPA activity and is present in plasma, platelets, and the subendothelium. Elevated PAI-1 levels, as occur in obesity, metabolic syndrome, and acute illness, impair fibrinolysis and contribute to thrombotic risk. Alpha-2-antiplasmin (alpha-2-AP) is a serpin that rapidly inactivates free (non-fibrin-bound) plasmin with a half-life for the plasmin-alpha-2-AP reaction of less than 100 milliseconds, providing the primary defense against systemic plasminemia. Fibrin-bound plasmin is substantially protected from alpha-2-AP inactivation, which is the mechanistic basis for the fibrin specificity of the therapeutic window for plasmin activity. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase that removes C-terminal lysine residues from partially degraded fibrin, reducing plasminogen binding sites on the fibrin surface and attenuating fibrinolysis; TAFI is activated by the thrombin-thrombomodulin complex and represents a physiological link between the coagulation and fibrinolytic systems.1
Plasminogen activators work by cleaving plasminogen to plasmin at the thrombus surface. Fibrin specificity (tPA >> uPA > streptokinase) determines the degree of systemic fibrinogenolysis: non-fibrin-specific agents deplete circulating fibrinogen and cause a systemic lytic state with higher bleeding risk. D-dimer is the clinical biomarker of plasmin-mediated fibrin degradation. PAI-1 is the principal endogenous brake on tPA activity; elevated PAI-1 impairs thrombolytic efficacy. Alpha-2-antiplasmin is the primary defense against systemic plasmin; when overwhelmed by exogenous thrombolytics, systemic fibrinogenolysis and bleeding risk escalate.
Four thrombolytic agents are in current clinical use: alteplase, tenecteplase, reteplase, and streptokinase. The first three are recombinant tPA-based agents with varying degrees of fibrin specificity and pharmacokinetic profiles designed to optimize clinical use; streptokinase remains relevant in resource-limited settings despite its lower fibrin specificity and immunogenicity. Selecting among them requires understanding how their pharmacological differences translate to practical considerations of dosing convenience, fibrin specificity, efficacy, and cost.
Alteplase: The Reference tPA. Alteplase is recombinant human tissue-type plasminogen activator (rt-PA) with a molecular structure identical to endogenous tPA, consisting of five structural domains: a fibronectin finger domain, an epidermal growth factor (EGF) domain, two kringle domains (K1 and K2), and the serine protease catalytic domain. The K2 kringle domain mediates high-affinity binding to fibrin, providing the fibrin specificity that concentrates plasminogen activation at the clot surface. Alteplase has a plasma half-life of approximately 3 to 5 minutes due to rapid hepatic clearance via low-density lipoprotein receptor-related protein (LRP) receptors and inhibition by PAI-1 (plasminogen activator inhibitor-1). This short half-life necessitates continuous intravenous infusion rather than single-bolus administration for most indications. The standard dosing regimen for STEMI [ST-segment elevation MI, where ST = the electrocardiographic ST segment] is the accelerated or front-loaded regimen: 15 mg IV bolus, then 0.75 mg/kg over 30 minutes (maximum 50 mg), then 0.5 mg/kg over 60 minutes (maximum 35 mg), for a maximum total dose of 100 mg over 90 minutes. For acute ischemic stroke (AIS), the dose is 0.9 mg/kg (maximum 90 mg total), with 10% of the total dose given as an IV bolus over 1 minute and the remainder infused over 60 minutes. For massive pulmonary embolism (PE), the regimen is 100 mg IV over 2 hours.27
Tenecteplase: Engineered for Single-Bolus Administration. Tenecteplase (TNK-tPA) is a bioengineered variant of alteplase with three amino acid substitutions designed to improve pharmacokinetic and pharmacodynamic properties: a substitution at position 103 (Thr→Asn) adds an N-linked glycosylation site that reduces hepatic clearance, extending the plasma half-life to approximately 20 to 24 minutes; a substitution at position 117 (Asn→Gln) removes a glycosylation site that competes with fibrin binding in the K1 domain, improving fibrin specificity; and substitutions at four positions in the protease domain render tenecteplase approximately 80-fold more resistant to PAI-1 (plasminogen activator inhibitor-1) inhibition than alteplase, enhancing activity in the platelet-rich arterial thrombus environment. The extended half-life allows single intravenous bolus administration, simplifying clinical use in out-of-hospital and emergency settings. Tenecteplase is weight-dosed for STEMI (ST-elevation myocardial infarction): 30 mg for weight below 60 kg, 35 mg for 60 to 69 kg, 40 mg for 70 to 79 kg, 45 mg for 80 to 89 kg, and 50 mg for 90 kg or above, all as a single IV bolus over 5 to 10 seconds.
Tenecteplase: ASSENT-2 Trial Evidence. The ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) trial (n = 16,949) demonstrated non-inferiority of tenecteplase versus alteplase for 30-day mortality in STEMI with significantly less non-cerebral major bleeding and fewer blood transfusions, establishing tenecteplase as the preferred fibrinolytic for STEMI in many contemporary protocols.4
Reteplase: Double-Bolus Recombinant tPA. Reteplase is a deletion mutant of alteplase that retains only the K2 kringle domain and the serine protease domain, lacking the fibronectin finger domain and EGF domain of native tPA. The deletion of the finger domain removes the primary hepatic clearance pathway (LRP-mediated) of tPA, extending the plasma half-life to approximately 13 to 16 minutes. However, the finger domain also contributes to fibrin binding, so reteplase has somewhat lower fibrin specificity than alteplase. The practical advantage is that reteplase can be administered as two fixed-dose IV boluses of 10 units (10 + 10 U), separated by 30 minutes, without weight-based dosing adjustment. In the GUSTO (Global Use of Strategies to Open Occluded Arteries) III trial, reteplase was non-inferior to alteplase for 30-day mortality in STEMI. Reteplase is FDA-approved for STEMI and acute myocardial infarction (AMI) with ST elevation but is not approved for acute ischemic stroke or pulmonary embolism. Its weight-independent dosing and double-bolus regimen make it convenient but offer no meaningful efficacy advantage over tenecteplase for STEMI.2
Streptokinase: Non-Fibrin-Specific Fibrinolytic. Streptokinase is a 47-kDa non-enzymatic protein produced by group C beta-hemolytic streptococci that forms a 1:1 equimolar complex with plasminogen, inducing a conformational change that creates an active site capable of cleaving and activating free plasminogen throughout the circulation regardless of fibrin binding. Because it activates plasminogen in the systemic circulation as well as at the clot surface, streptokinase produces a systemic lytic state characterized by consumption of plasminogen, fibrinogen, and fibrin, generating large amounts of FDPs that themselves have anticoagulant properties by competing with fibrinogen for fibrin polymerization sites. Streptokinase is antigenic and stimulates antibody formation after exposure; prior streptococcal infection or prior streptokinase administration can produce antibody titers sufficient to neutralize a subsequent therapeutic dose, making repeat administration within 6 to 12 months ineffective. Streptokinase is administered as 1.5 million units IV over 60 minutes for STEMI. Despite its disadvantages, streptokinase remains relevant in many lower-income countries where the cost differential from recombinant agents is clinically significant. It is not approved or used for stroke (hemorrhagic risk in the systemic lytic state is prohibitive) or PE management in the United States.2
Alteplase: highest fibrin specificity among approved agents; requires weight-based infusion over 90 min (STEMI) or 60 min (stroke, PE); universal approval. Tenecteplase: single weight-based IV bolus; highest PAI-1 resistance; less non-cerebral bleeding than alteplase; preferred for STEMI in many protocols. Reteplase: two fixed 10-unit boluses 30 min apart; no weight adjustment; non-inferior to alteplase for STEMI; not approved for stroke or PE. Streptokinase: non-fibrin-specific; antigenic (no repeat within 6–12 months); 1.5 million units over 60 min; STEMI only; lowest cost but highest systemic bleeding risk and no role in stroke.
The clinical application of thrombolytic therapy is defined by three major indications: STEMI [ST-segment elevation myocardial infarction, ST = electrocardiographic ST segment] requiring PCI (percutaneous coronary intervention) or fibrinolysis, acute ischemic stroke, and massive pulmonary embolism. Each indication has distinct time windows, evidence bases, preferred agents, dosing regimens, and criteria for selecting pharmacological over mechanical reperfusion. The common thread across all three is that benefit is time-dependent and that the risk-benefit ratio of thrombolysis shifts unfavorably as time from symptom onset increases.
STEMI: Fibrinolysis Versus Primary PCI. In STEMI (ST-segment elevation myocardial infarction), confirmed by ECG (electrocardiogram), the coronary artery is occluded by a platelet-rich thrombus superimposed on a ruptured atherosclerotic plaque, and restoration of coronary flow is time-critical. Primary PCI (percutaneous coronary intervention) is the preferred reperfusion strategy when it can be performed within 120 minutes of first medical contact (FMC) with a door-to-balloon time of 90 minutes or less at a PCI-capable center. Fibrinolytic therapy is indicated when primary PCI cannot be delivered within 120 minutes of FMC, provided there are no contraindications. Fibrinolysis is most effective when administered early: benefit is greatest within 3 hours of symptom onset, with a number needed to treat of approximately 10 in the first hour (the "golden hour"), declining substantially beyond 6 hours. The GISSI-1 (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) trial established that intravenous streptokinase reduces 21-day mortality in STEMI.3
STEMI Fibrinolysis: Pharmacoinvasive Strategy. Subsequent trials demonstrated superiority of fibrin-specific agents (tPA) over streptokinase and primary PCI over fibrinolysis when PCI is promptly available. If fibrinolysis is chosen and achieves successful reperfusion (defined by symptom relief, ST-segment resolution greater than 50% at 60 to 90 minutes, and reperfusion arrhythmia), routine early coronary angiography at 3 to 24 hours (pharmacoinvasive strategy) is recommended to identify the culprit lesion and consider PCI. Failed fibrinolysis (less than 50% ST resolution at 90 minutes) requires immediate rescue PCI.34
Acute Ischemic Stroke: Time Windows and Patient Selection. Alteplase is the only FDA-approved thrombolytic for acute ischemic stroke (AIS) and represents the most evidence-based pharmacological intervention in stroke management. The time window for IV alteplase is within 4.5 hours of stroke symptom onset (or last known well time) based on evidence from the NINDS (National Institute of Neurological Disorders and Stroke) tPA stroke trial (0 to 3 hours) and ECASS-3 (European Cooperative Acute Stroke Study) trial (3 to 4.5 hours). In the NINDS trial, alteplase-treated patients were 30% more likely to have minimal or no disability at 3 months compared with placebo; the benefit was achieved at the cost of a 6-fold increase in symptomatic intracranial hemorrhage (sICH) rate (6.4% vs. 0.6%), which did not translate to an increase in 3-month mortality, demonstrating that the functional benefit outweighs the hemorrhagic risk in appropriately selected patients. The 0 to 3 hour window carries the greatest absolute benefit.56
Acute Ischemic Stroke: ECASS-3 Window and Tenecteplase Evidence. The ECASS-3 trial extended the window to 4.5 hours but excluded patients aged above 80 years, those on oral anticoagulants, those with prior stroke plus diabetes, and those with NIHSS (National Institutes of Health Stroke Scale) scores above 25. Tenecteplase has been evaluated in AIS in several trials including TASTE-A (Tenecteplase in Stroke Patients for Assessment of Context-Specific Efficacy) and NOR-TEST (Norwegian Tenecteplase Stroke Trial) and is approved for AIS in Australia and several European countries; accumulating evidence and its single-bolus convenience are driving ongoing regulatory review in the United States, but alteplase remains the FDA-approved standard of care as of 2025.56
Stroke Thrombolysis: Patient Selection Criteria. Appropriate patient selection for IV alteplase in AIS requires confirming the diagnosis of ischemic (not hemorrhagic) stroke by non-contrast brain computed tomography (CT) scan, establishing time of onset, and screening for contraindications. Key eligibility criteria include: age 18 years or above, measurable neurological deficit, and CT scan showing no hemorrhage or established large infarct (greater than one-third of the middle cerebral artery territory). Blood pressure must be below 185/110 mmHg at the time of treatment and maintained below 180/105 mmHg for at least 24 hours after thrombolysis; antihypertensive agents (labetalol IV or nicardipine IV infusion) are used to achieve this threshold if needed. Blood glucose must be above 50 mg/dL. An evolving infarct visible on CT reduces benefit; patients with large early ischemic changes (hypodensity involving more than one-third of the MCA territory) have a higher risk of hemorrhagic transformation and are generally excluded. Mechanical thrombectomy (endovascular clot retrieval) has largely replaced fibrinolysis for large vessel occlusion stroke when thrombectomy can be performed within 24 hours of onset; IV alteplase is still administered as a bridge prior to thrombectomy in eligible patients.56
Pulmonary Embolism: Systemic Thrombolysis. Thrombolytic therapy in PE (pulmonary embolism) is stratified by hemodynamic severity. In massive PE (high-risk PE), defined by hemodynamic instability (systolic blood pressure below 90 mmHg for 15 minutes or more, requirement for vasopressors, cardiac arrest, or signs of severe RV [right ventricular] failure), systemic IV thrombolysis is indicated unless there are absolute contraindications. Alteplase 100 mg IV over 2 hours is the standard regimen; a rapid infusion of 0.6 mg/kg (maximum 50 mg) over 15 minutes may be used in cardiac arrest. The PEITHO (Pulmonary Embolism Thrombolysis) trial examined thrombolysis in submassive (intermediate-risk) PE and found that tenecteplase reduced the composite primary outcome of hemodynamic decompensation or death but at the cost of significantly increased major bleeding and stroke, informing a conservative approach in hemodynamically stable patients.78
Catheter-Directed Thrombolysis for PE. Catheter-directed thrombolysis (CDT) involves advancing a multi-sidehole catheter directly into the thrombus and infusing low-dose alteplase (approximately 0.5 to 1 mg/hr per catheter, total dose typically 8 to 24 mg over 12 to 24 hours) locally, reducing the systemic thrombolytic dose by approximately 90% compared with systemic administration. CDT offers an intermediate option for intermediate-high-risk PE with evidence of RV dysfunction. The ULTIMA (Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism) trial demonstrated superior RV/LV (right ventricular to left ventricular diameter) ratio improvement versus anticoagulation alone at 24 hours, supporting CDT as a tool to reduce RV strain while minimizing systemic bleeding exposure.78
STEMI: fibrinolysis if PCI not available within 120 min of FMC; best within 3 h; tenecteplase single bolus preferred; pharmacoinvasive strategy (early angio at 3–24 h) after successful lysis. Acute ischemic stroke: alteplase 0.9 mg/kg within 4.5 h; confirm ischemic by CT; BP <185/110 mmHg before treatment; thrombectomy for large vessel occlusion. Massive PE: alteplase 100 mg over 2 h; systemic for hemodynamic instability. Submassive PE: anticoagulation preferred; CDT for intermediate-high risk with RV dysfunction. Catheter-directed thrombolysis: 0.5–1 mg/hr alteplase, total 8–24 mg, reduces systemic dose by ∼90%.
The central clinical challenge in thrombolytic therapy (applicable to all indications including STEMI [ST-segment elevation MI, where ST denotes the electrocardiographic ST segment], stroke, and PE (pulmonary embolism)) is preventing life-threatening bleeding complications, of which intracranial hemorrhage is the most feared. Contraindication screening before administration, vigilant post-thrombolysis monitoring, and rapid initiation of reversal strategies when bleeding occurs are the three pillars of safe thrombolytic use. Antifibrinolytic agents (tranexamic acid and aminocaproic acid) provide the pharmacological foundation for reversing both thrombolytic-induced bleeding and other fibrinolysis-driven hemorrhagic conditions.
Absolute Contraindications to Thrombolysis. Absolute contraindications apply to all thrombolytic agents and all indications, representing scenarios where the risk of life-threatening bleeding is certain or so high that no expected benefit of thrombolysis could justify the risk. For acute ischemic stroke thrombolysis, absolute contraindications include: any prior intracranial hemorrhage (intracerebral hemorrhage [ICH] or subarachnoid hemorrhage [SAH]); ischemic stroke or serious head trauma within the preceding 3 months; intracranial or intraspinal surgery within 3 months; active internal bleeding other than menstruation; intracranial neoplasm, arteriovenous malformation (AVM), or aneurysm; current anticoagulation with international normalized ratio (INR) above 1.7 or direct oral anticoagulant (DOAC) taken within 48 hours in the setting of normal renal function; platelet count below 100,000/mcL; blood glucose below 50 mg/dL (neurological deficits may resolve with glucose correction); blood pressure persistently above 185/110 mmHg despite antihypertensive treatment; and computed tomography (CT) evidence of established large infarct involving more than one-third of the MCA (middle cerebral artery) territory or intracranial hemorrhage. For thrombolysis in STEMI (ST-segment-elevation myocardial infarction) and PE (pulmonary embolism), absolute contraindications include prior intracranial hemorrhage, known structural cerebrovascular lesion, ischemic stroke within 3 months, active bleeding diathesis (excluding menses), significant closed head trauma or facial trauma within 3 months, and intracranial or intraspinal surgery within 2 months.35
Relative Contraindications. Relative contraindications represent scenarios where the risk of bleeding is elevated but where thrombolysis may still be appropriate if the clinical benefit is judged to outweigh the risk, particularly in life-threatening indications such as massive PE or large-territory ischemic stroke. For stroke thrombolysis, relative contraindications include: minor or rapidly improving stroke symptoms (the risk-benefit may not favor treatment for mild deficits); seizure at stroke onset (though this is no longer an absolute contraindication in many guidelines if MRI (magnetic resonance imaging) or CT perfusion imaging confirms ischemia); major surgery or serious non-intracranial trauma within 14 days; recent internal bleeding within 21 days; arterial puncture at a non-compressible site within 7 days; pregnancy; active peptic ulcer disease; and age above 80 years for the 3 to 4.5 hour window (though age alone is not an absolute contraindication for the 0 to 3 hour window). For STEMI and PE thrombolysis, relative contraindications include active peptic ulcer disease, severe uncontrolled hypertension, anticoagulant therapy in therapeutic range, traumatic or prolonged cardiopulmonary resuscitation (CPR) (greater than 10 minutes), major surgery within 3 weeks, prior exposure to streptokinase within 6 to 12 months (for streptokinase only), pregnancy, and advanced liver disease.35
Intracranial Hemorrhage: Recognition and Management. Symptomatic intracranial hemorrhage (sICH) following thrombolysis is the most devastating complication, occurring in approximately 2 to 6% of stroke patients and 0.5 to 1% of STEMI and PE patients treated with systemic fibrinolytics. Risk factors for post-thrombolysis sICH include advanced age, higher NIHSS (stroke scale) score at presentation, hyperglycemia, elevated blood pressure, early ischemic changes on CT scan, anticoagulant use, and low platelet count. The clinical presentation is typically sudden neurological deterioration (altered consciousness, new focal deficit, or headache) occurring within 24 to 36 hours of thrombolytic administration. Management requires immediate cessation of all antithrombotic therapy, emergent CT scan of the head, and neurosurgical consultation. If the patient is still actively receiving the thrombolytic infusion, it must be stopped immediately. Laboratory evaluation should include complete blood count (CBC), prothrombin time (PT) / INR, activated partial thromboplastin time (aPTT), fibrinogen level, and type and crossmatch. Fibrinogen levels below 150 mg/dL confirm a systemic lytic state requiring active replacement.59
Reversal of Thrombolytic Bleeding: Cryoprecipitate. Active bleeding following thrombolysis is managed by replacing consumed hemostatic proteins and inhibiting ongoing fibrinolytic activity. Cryoprecipitate (each unit contains approximately 150 to 250 mg of fibrinogen, as well as factor VIII, factor XIII, vWF [von Willebrand factor], and fibronectin) is the preferred product for rapid fibrinogen replacement in thrombolytic-associated bleeding; the target fibrinogen level is above 150 mg/dL. The standard empirical dose is 10 units of cryoprecipitate IV, each unit raising fibrinogen by approximately 5 to 7 mg/dL in an average adult; the dose is repeated until the fibrinogen target is achieved. Fresh frozen plasma (FFP) contains fibrinogen at a much lower concentration (approximately 2 to 3 mg/mL per unit) compared with cryoprecipitate (approximately 15 to 30 mg/mL per unit), making cryoprecipitate far more volume-efficient for fibrinogen replacement specifically.9
Antifibrinolytic Agents for Thrombolytic Reversal. Antifibrinolytic agents — tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) — are the pharmacological cornerstone of thrombolytic reversal. Both are lysine analogues that competitively inhibit the lysine-binding sites in plasminogen kringle domains, blocking plasminogen binding to fibrin and preventing plasminogen activation by tPA. TXA (tranexamic acid) is given as 10 to 15 mg/kg IV over 10 minutes; EACA (epsilon-aminocaproic acid) is given as a 5 g IV loading dose over 15 to 30 minutes followed by 1 to 1.25 g/hr infusion. Platelet transfusion is indicated if the platelet count falls below 100,000/mcL in the setting of active bleeding. For ongoing hemorrhagic shock unresponsive to the above measures, recombinant activated factor VII (rFVIIa) has been used off-label.9
Tranexamic Acid: Broader Clinical Applications. Beyond thrombolytic reversal, tranexamic acid (TXA) has established roles in reducing surgical blood loss and in trauma hemorrhage. The CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) trial (n = 20,211 trauma patients with significant hemorrhage) demonstrated that TXA given within 3 hours of injury reduced all-cause mortality by approximately 9% relative risk (14.5% vs. 16.0%) and death due to bleeding, with no increase in vascular occlusive events; the benefit was time-dependent, with no benefit and possibly harm when TXA was given more than 3 hours after injury. In major elective surgery including cardiac surgery, joint arthroplasty, and spine surgery, TXA reduces intraoperative blood loss and allogeneic transfusion requirements by 30 to 40%. In post-partum hemorrhage, TXA given within 3 hours of delivery reduces blood loss and mortality from hemorrhage. TXA is generally well tolerated; the primary adverse effect of concern is venous thromboembolism (VTE), though the absolute risk increase appears small at recommended doses. It is contraindicated in patients with active intravascular clotting or a history of venous or arterial thrombosis without adequate anticoagulation, and should be used with caution in patients with subarachnoid hemorrhage (where it reduces rebleeding but may increase cerebral vasospasm and ischemic complications at higher doses).910
Stop thrombolytic infusion immediately. Emergent CT head if neurological deterioration. CBC, PT/INR, aPTT, fibrinogen level, type and crossmatch. If fibrinogen <150 mg/dL: give 10 units cryoprecipitate IV; recheck fibrinogen; repeat until ≥150 mg/dL. Antifibrinolytic: tranexamic acid 10–15 mg/kg IV over 10 min OR aminocaproic acid 5 g IV load then 1 g/hr. If platelets <100,000/mcL with active bleeding: platelet transfusion. Avoid anticoagulants and antiplatelets for at least 24 hours after stroke thrombolysis. Neurosurgical consultation for ICH. Maintain systolic BP <180 mmHg to reduce hemorrhagic expansion.
Procoagulant and hemostatic agents encompass a pharmacologically diverse set of drugs united by their clinical function: reversing the effects of anticoagulants or directly restoring hemostatic capacity in the setting of bleeding. This class includes vitamin K for warfarin reversal, protamine sulfate for heparin reversal, and the newer targeted reversal agents — idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors — alongside non-specific procoagulant products such as prothrombin complex concentrates and fresh frozen plasma.
Vitamin K (Phytonadione): Mechanism and Onset. Vitamin K (phytonadione, vitamin K1) is the essential cofactor for the gamma-carboxylation of glutamic acid residues in the vitamin K-dependent coagulation factors — factor II (prothrombin), factor VII, factor IX, and factor X — as well as the anticoagulant proteins C and S. Warfarin acts by inhibiting VKOR (vitamin K epoxide reductase), depleting reduced vitamin K and preventing gamma-carboxylation. Exogenous phytonadione restores VKOR substrate availability and reverses warfarin anticoagulation, but the onset is delayed because new factor synthesis is required: factor VII, with the shortest half-life of approximately 4 to 6 hours, is the first to recover, whereas prothrombin (factor II, half-life approximately 60 to 72 hours) recovers last. Intravenous vitamin K produces measurable INR (international normalized ratio) reduction within 6 to 8 hours and near-complete reversal within 12 to 24 hours; oral vitamin K achieves INR correction within 24 to 48 hours.
Vitamin K: Dosing and Route Selection. For life-threatening bleeding or emergency surgery, vitamin K must be combined with PCC (prothrombin complex concentrate) or FFP (fresh frozen plasma) to achieve immediate factor replacement while vitamin K restores endogenous factor synthesis. For non-urgent warfarin reversal (INR above goal but no active bleeding), oral vitamin K 2.5 to 5 mg is effective and preferred. For urgent reversal, IV vitamin K 5 to 10 mg combined with 4-factor PCC provides the most rapid and complete reversal strategy. The IV route carries a small risk of anaphylaxis (estimated 1 in 10,000 doses) when administered rapidly; the recommended maximum IV infusion rate is 1 mg/min.11
Protamine Sulfate: Heparin Reversal Mechanism and Dosing. Protamine sulfate is a highly positively charged protein (derived from salmon sperm) that reverses UFH (unfractionated heparin) anticoagulation by forming a stable ionic complex with the polyanionic heparin molecule, rendering it pharmacologically inactive. The complex is then cleared by the reticuloendothelial system. Protamine neutralization of UFH is rapid (within minutes) and nearly complete; the dose required is 1 mg protamine per 100 units of UFH administered in the preceding 2 to 3 hours. Protamine has more limited and less predictable activity against LMWH (low molecular weight heparin): it completely neutralizes the anti-IIa (thrombin-inhibiting) activity of LMWH but only partially neutralizes anti-Xa activity (approximately 60 to 75%), because the shorter saccharide chains of LMWH have lower protamine binding affinity. For enoxaparin reversal, the recommended dose is 1 mg protamine per 1 mg enoxaparin if given within 8 hours of the last LMWH dose. Protamine has no activity against fondaparinux (a pure synthetic pentasaccharide).
Protamine Adverse Effects. Adverse effects of protamine include bradycardia and hypotension (from histamine release and complement activation), pulmonary hypertension (in high doses, from pulmonary vasoconstriction), and anaphylaxis, which is more frequent in patients with prior protamine or salmon exposure or NPH (neutral protamine Hagedorn) insulin use, which contains protamine as a carrier protein. A second protamine dose of 0.5 mg per 1 mg enoxaparin can be given if bleeding continues after the first LMWH reversal dose.12
Idarucizumab: Specific Dabigatran Reversal. Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment (Fab) developed specifically to reverse the anticoagulant effect of dabigatran, the direct thrombin inhibitor (DTI). Idarucizumab binds dabigatran with an affinity approximately 350 times greater than dabigatran's affinity for thrombin, forming an irreversible 1:1 complex that neutralizes dabigatran immediately upon administration. It has no activity against any other anticoagulant. The approved dose is 5 g IV, administered as two separate 2.5 g IV boluses given no more than 15 minutes apart. In the Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD) trial (n = 503), idarucizumab produced immediate, complete, and sustained reversal of dabigatran anticoagulation (as measured by dilute thrombin time and ecarin clotting time) in patients with serious bleeding or who required urgent surgery. The median maximum reversal was 100%. Idarucizumab is rapidly cleared by the kidney; the dabigatran-idarucizumab complex is excreted in urine. Rebound dabigatran anticoagulation can occur within 12 to 24 hours in patients with high dabigatran body burden (particularly those with renal impairment in whom dabigatran clearance is reduced), because dabigatran sequestered in tissues redistributes into plasma after idarucizumab is cleared. A second 5 g dose of idarucizumab can be given if rebound occurs with clinical manifestations.13
Andexanet Alfa: Mechanism and Clinical Evidence. Andexanet alfa (Andexxa) is a modified recombinant inactive form of human factor Xa (FXa) that acts as a decoy receptor: it binds and sequesters factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, and betrixaban) in the circulation, reducing the free drug concentration available to inhibit native factor Xa and thereby restoring hemostasis. The catalytic serine of factor Xa has been mutated to render andexanet enzymatically inactive, preventing thrombin generation while retaining factor Xa inhibitor binding affinity. Andexanet also binds TFPI (tissue factor pathway inhibitor), which may contribute a procoagulant effect beyond direct Xa inhibitor neutralization. In the Andexanet Alfa — a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors trial (ANNEXA-4) (n = 352), andexanet alfa given to patients with factor Xa inhibitor-associated life-threatening bleeding produced good or excellent hemostasis in 82% of patients at 12 hours.14
Andexanet Alfa: Dosing and Safety. Dosing depends on the specific agent, dose, and timing of last administration. The low-dose regimen (400 mg IV bolus followed by 480 mg IV over 2 hours) is used for rivaroxaban 10 mg or less, apixaban 5 mg or less, or any dose taken more than 8 hours before treatment. The high-dose regimen (800 mg IV bolus followed by 960 mg IV over 2 hours) is used for rivaroxaban above 10 mg, apixaban above 5 mg, or edoxaban taken within 8 hours. Andexanet is not approved for fondaparinux reversal. Thrombotic events (including ischemic stroke, MI [myocardial infarction], and VTE [venous thromboembolism]) occurred in approximately 10% of ANNEXA-4 patients within 30 days, consistent with the severity of the underlying conditions and the procoagulant effect of reversal.14
Four-Factor PCC: Composition, Dosing, and Warfarin Reversal. Four-factor PCC (prothrombin complex concentrate; 4F-PCC, Kcentra in the US) contains all four VKA (vitamin K antagonist)-dependent coagulation factors (factors II, VII, IX, and X) as well as proteins C and S, in a highly concentrated lyophilized form administered in a small volume (typically 100 to 250 mL). It is the preferred agent for urgent reversal of VKA anticoagulation in patients with life-threatening bleeding or emergency surgery, achieving INR (international normalized ratio) correction within 15 to 30 minutes regardless of the starting INR. The dose is weight-based and INR-guided: for INR 2 to 3.9, 25 units/kg (maximum 2,500 units); INR 4 to 6, 35 units/kg (maximum 3,500 units); INR above 6, 50 units/kg (maximum 5,000 units). 4F-PCC must always be accompanied by IV vitamin K to prevent factor level rebound as PCC is cleared (half-life approximately 6 to 24 hours depending on factor).11
Fresh Frozen Plasma and Non-Specific Reversal Strategies. FFP (fresh frozen plasma) contains all clotting factors at normal plasma concentrations but requires large volumes (typically 15 to 20 mL/kg, or 4 to 6 units) to correct severe coagulopathy, carries risks of fluid overload and TRALI (transfusion-related acute lung injury), and requires 30 minutes of thawing before administration. FFP remains standard for factor replacement in the absence of specific reversal agents (factor XI deficiency, liver disease coagulopathy) and in consumptive coagulopathy such as DIC (disseminated intravascular coagulation) where a broad replacement strategy is needed. In the context of DOAC (direct oral anticoagulant) reversal, 4F-PCC at 50 units/kg is the best available non-specific alternative when idarucizumab (for dabigatran) or andexanet alfa (for factor Xa inhibitors) are unavailable, partially reversing Xa inhibitor anticoagulation by overwhelming inhibition with excess factor substrate.1112
UFH: protamine sulfate 1 mg per 100 units UFH (last 2–3 h) IV slow push. LMWH: protamine 1 mg per 1 mg enoxaparin (within 8 h); partial anti-Xa reversal only. Fondaparinux: no specific reversal; 4F-PCC or rFVIIa off-label. Warfarin life-threatening bleed: 4F-PCC (dose by INR) + IV vitamin K 10 mg. Warfarin non-urgent: oral vitamin K 2.5–5 mg. Dabigatran: idarucizumab 5 g IV (two 2.5 g boluses). Apixaban/rivaroxaban: andexanet alfa (low or high dose per agent/timing); 4F-PCC 50 units/kg if andexanet unavailable. All DOAC reversals: resume anticoagulation when hemostasis achieved and indication warrants.
Clinical decision-making in thrombolytic and procoagulant pharmacology — encompassing STEMI (ST [electrocardiographic ST-segment]-elevation myocardial infarction), ischemic stroke, and PE (pulmonary embolism) reversal — requires integrating the urgency of the indication, the availability of specific reversal agents, the presence of contraindications, and the timing of subsequent antithrombotic therapy after thrombolysis or reversal. This section synthesizes the preceding material into actionable clinical frameworks for the three major thrombolytic indications and for anticoagulant reversal decision trees.
Post-Thrombolysis Anticoagulation in STEMI. Following successful fibrinolysis in STEMI (ST-segment-elevation myocardial infarction), anticoagulation is required to prevent reocclusion of the infarct-related artery and to support the pharmacoinvasive strategy. Anticoagulant therapy should be initiated or continued after fibrinolysis for a minimum of 48 hours or until revascularization (whichever comes first). Recommended regimens include enoxaparin (preferred over UFH [unfractionated heparin] based on the ExTRACT-TIMI 25 [Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment] trial): 30 mg IV bolus, then 1 mg/kg SC (subcutaneous) every 12 hours; for patients aged 75 years or above, the IV bolus is omitted and the SC dose is 0.75 mg/kg every 12 hours; for CrCl (creatinine clearance) below 30 mL/min, the dose is reduced to 1 mg/kg once daily.3
Post-STEMI Thrombolysis: UFH, Fondaparinux, and Antiplatelet Therapy. UFH is given as a 60 units/kg IV bolus (maximum 4,000 units) followed by 12 units/kg/hr (maximum 1,000 units/hr), adjusted to maintain aPTT (activated partial thromboplastin time) 50 to 70 seconds. Fondaparinux 2.5 mg SC once daily may be used in patients not receiving early invasive management. Dual antiplatelet therapy with aspirin and a P2Y12 (purinergic receptor) inhibitor is initiated at the time of fibrinolysis and continued per STEMI guidelines (see Module 05 for DAPT duration details). Clopidogrel 300 mg loading dose (75 mg in patients aged 75 years or above) is the preferred P2Y12 agent combined with fibrinolysis; prasugrel and ticagrelor are not recommended in combination with fibrinolysis due to concern for additive intracranial hemorrhage risk.34
Post-Thrombolysis Management in Acute Ischemic Stroke. After IV alteplase administration for acute ischemic stroke, antithrombotic therapy must be held for 24 hours to minimize the risk of hemorrhagic transformation of the ischemic infarct. Brain CT (computed tomography) or MRI (magnetic resonance imaging) at 24 hours is performed before resuming any antiplatelet or anticoagulant therapy. If the 24-hour imaging shows no hemorrhagic transformation, antiplatelet therapy (aspirin 325 mg, then 81 to 325 mg daily) is resumed at 24 hours for most patients with non-cardioembolic ischemic stroke. For patients with atrial fibrillation (AF) who require oral anticoagulation for stroke prevention, anticoagulation initiation after thrombolysis is typically deferred for 4 to 14 days depending on infarct size and the risk of hemorrhagic transformation assessed on neuroimaging; large infarcts or evidence of hemorrhagic transformation warrant the longer deferral period. Blood pressure management after thrombolysis requires maintaining systolic BP (blood pressure) below 180 mmHg and diastolic BP below 105 mmHg for at least 24 hours to reduce hemorrhagic transformation risk. Mechanical thrombectomy can be performed immediately after IV alteplase infusion for eligible patients with large vessel occlusion without waiting for the alteplase infusion to complete. Intra-arterial heparin is used during the thrombectomy procedure as part of standard interventional technique but is not given as a therapeutic anticoagulant post-procedure without specific indications.56
Anticoagulant Reversal Decision Framework. Selecting among reversal strategies requires knowing the specific anticoagulant, the severity and location of bleeding, the time since the last dose, and relevant organ function. For VKA (vitamin K antagonist) anticoagulation, the INR (international normalized ratio) defines urgency: INR above therapeutic range without bleeding (over-anticoagulation) is managed with low-dose oral vitamin K (1 to 2.5 mg for INR 4 to 10, 2.5 to 5 mg for INR above 10) and withholding of warfarin doses; minor bleeding requires vitamin K 2.5 to 5 mg orally or IV; major or life-threatening bleeding requires 4F-PCC plus IV vitamin K 10 mg simultaneously. The 4F-PCC dose is weight and INR-based as described above.11
DOAC Reversal Decision Framework. For DOAC (direct oral anticoagulant) reversal, the first question is which agent: dabigatran, a DTI (direct thrombin inhibitor), receives idarucizumab; factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) receive andexanet alfa if available. The second question is severity: life-threatening bleeding or emergency surgery requiring immediate reversal within 8 hours. If specific reversal agents are unavailable, 4F-PCC at 50 units/kg is the best available non-specific alternative for Xa inhibitor reversal; activated charcoal (50 g orally) can reduce gut absorption if the DOAC was taken within 2 to 4 hours. Hemodialysis can remove dabigatran (which is approximately 35% protein-bound and dialyzable) but is not effective for the highly protein-bound factor Xa inhibitors.11121314
Disseminated Intravascular Coagulation: Procoagulant and Antifibrinolytic Strategy. Disseminated intravascular coagulation (DIC) is a syndrome of systemic activation of coagulation leading to simultaneous microvascular thrombosis (consuming clotting factors and platelets) and secondary fibrinolysis (causing bleeding from depletion of hemostatic factors). Management of DIC focuses primarily on treating the underlying cause (sepsis, obstetric emergency, malignancy, trauma) while providing supportive hemostatic replacement. FFP (fresh frozen plasma) replaces all consumed clotting factors; cryoprecipitate replaces fibrinogen specifically (target above 150 mg/dL); platelet transfusion targets above 50,000/mcL with active bleeding. Heparin has a limited role in DIC and is generally reserved for DIC with predominant thrombotic manifestations (purpura fulminans, acral ischemia) rather than bleeding-predominant DIC.15
DIC: Antifibrinolytic Considerations. Antifibrinolytic agents such as TXA (tranexamic acid) are generally avoided in DIC (disseminated intravascular coagulation) because fibrinolysis in DIC is reactive and protective against microvascular thrombosis; suppressing it risks worsening organ ischemia. The exception is DIC associated with acute promyelocytic leukemia (APL), where a primary hyperfibrinolytic state often predominates and TXA can be beneficial before all-trans retinoic acid (ATRA) treatment takes effect.15
Thrombolytics: alteplase (reference agent, all indications), tenecteplase (single bolus, STEMI preferred), reteplase (double bolus, STEMI), streptokinase (non-fibrin-specific, resource-limited). Post-thrombolysis: STEMI requires anticoagulation ≥48 h + DAPT; stroke requires 24 h antithrombotic hold then imaging-guided resumption. Contraindication screening is mandatory before every thrombolytic administration. Reversal: tranexamic acid + cryoprecipitate for fibrinolytic bleeding; idarucizumab for dabigatran; andexanet alfa for Xa inhibitors; 4F-PCC + vitamin K for warfarin; protamine for heparin/LMWH. DIC: treat cause, replace factors/platelets; avoid antifibrinolytics except in APL.
Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307-321.
doi:10.1111/j.1365-2141.2005.05444.xAntman EM, Morrow DA. ST-elevation myocardial infarction: management. In: Libby P, et al., eds. Braunwald's Heart Disease. 12th ed. Philadelphia: Elsevier; 2022:504-540. ISBN: 9780323722193.
elsevier.com/books/braunwalds-heart-diseaseO'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78-e140.
doi:10.1016/j.jacc.2012.11.019Van de Werf F, Adgey J, Ardissino D, et al. (ASSENT-2). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-722.
doi:10.1016/S0140-6736(99)07403-6Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. Stroke. 2019;50(12):e344-e418.
doi:10.1161/STR.0000000000000211Hacke W, Kaste M, Bluhmki E, et al. (ECASS-3). Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
doi:10.1056/NEJMoa0804656Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
doi:10.1016/j.chest.2015.11.026Meyer G, Vicaut E, Danays T, et al. (PEITHO). Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411.
doi:10.1056/NEJMoa1302097Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. Neurocrit Care. 2016;24(1):6-46.
doi:10.1007/s12028-015-0222-xCRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. Lancet. 2010;376(9734):23-32.
doi:10.1016/S0140-6736(10)60835-5Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. ACCP guidelines. Chest. 2012;141(2 Suppl):e152S-e184S.
doi:10.1378/chest.11-2295Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111(10):4871-4879.
doi:10.1182/blood-2007-10-120543Pollack CV Jr, Reilly PA, van Ryn J, et al. (RE-VERSE AD). Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377(5):431-441.
doi:10.1056/NEJMoa1707278Connolly SJ, Crowther M, Eikelboom JW, et al. (ANNEXA-4). Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-1335.
doi:10.1056/NEJMoa1814051Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33.
doi:10.1111/j.1365-2141.2009.07600.x